Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
ADAG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.33 - $3.16
Previous CloseN/A
Volume1.51K
Average Volume (3M)111.04K
Market Cap
$92.38M
Enterprise Value$35.89M
Total Cash (Recent Filing)$62.83M
Total Debt (Recent Filing)$6.85M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Apr 01, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding47,109,554
10 Day Avg. Volume57,486
30 Day Avg. Volume111,043
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue347.78
Enterprise Value/Gross Profit-31.95
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$7.67Price Target Upside291.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical SuccessAdagene's conditionally masked CTLA-4 antagonist muzatotug (muza) is best-positioned for clinical and commercial success in relapsed/refractory microsatellite stable, non-liver metastatic colorectal cancer.
Regulatory MilestoneFDA alignment on trial design of both Phase 2 and 3 studies with ADG126 is seen as an important regulatory milestone, providing clarity on ADG126’s development path.
Strategic InvestmentAdagene announced a strategic investment of up to $25M from Sanofi, which strengthens its balance sheet to advance its proprietary pipeline.
Bears Say
Financial SustainabilityThe company ended the quarter with $62.8M in cash and cash equivalents, which the company states should sustain operations into 2027.
Market CompetitionAdagene’s clinical experience showcases the industry’s strongest demonstration of effective protease-masking and conditional activity of a potent IO therapy in the tumor microenvironment.
Adagene News
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.32 and its highest was $3.16 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $92.38M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Apr 01, 2026 which is in 184 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Aug 12, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.04.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.26.
How many shares outstanding does Adagene have?
Adagene has 47,109,554 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -13.613%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
Adagene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (291.33% Upside)
$7.67 (291.33% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-63.24%
Trailing 12-Months
Asset Growth
-34.00%
Trailing 12-Months
Company Description
Adagene
Adagene (ADAG) is a biotechnology company that operates in the pharmaceutical and life sciences sectors. The company specializes in the development of innovative antibody-based therapies, utilizing its proprietary Dynamic Precision Library (DPL) technology to create novel therapeutics targeting various diseases, including cancer. Adagene's core focus is on advancing its pipeline of products through clinical trials and strategic collaborations to bring effective treatments to market.
ADAG Stock 12 Month Forecast
Average Price Target
$7.67
▲(291.33% Upside)
Technical Analysis
Adverum Biotechnologies
―
Avalo Therapeutics
―
IGM Biosciences
―
Caribou Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
11.77% Other Institutional Investors
88.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---